Published June 11, 2025
| Version v0.0.6
Dataset
Open
Gadoxetate kinetics measured with MRI
Creators
-
1.
University of Manchester
-
2.
University of Sheffield
-
3.
Antaros Medical (Sweden)
- 4. Bioxydyn
-
5.
University of Leeds
- 6. Bayer
Description
Database
This database collects signal-time curves measured through the various experiments of the liver workpackage of the TRISTAN consortium. The database is maintained by the open medical imaging biomarkers laboratory (miblab.org).
Subjects
Human healthy volunteers, patients and rats.
Background
The data are taken from a series of preclinical and clinical studies performed by the TRISTAN project, in the period 2018-2024. The aim of these studies was to test if the effect of drugs on uptake and excretory function of the liver can be measured reliably with dynamic gadoxetate-enhanced MRI. Combined these studies provide proof of concept for a new MRI-based biomarker to predict the risk of liver-mediated drug-drug interactions, and of drug-induced liver injury.
The data have been used to support a submission to the FDA's biomarker qualification program (details).
Format
All data are in dmr format - a folder with three csv files:
- data.csv: Data dictionary
- rois.csv: ROI curves
- pars.csv: Subject parameters
The data can be read and manipulated interactively with common applications such as excel, or programmatically with the python package pydmr.
Example usage
- Rats multiple dosing: https://dcmri.org/examples/liver/plot_tristan_mdosing.html
- Rat six test drugs: https://dcmri.org/examples/liver/plot_tristan6drugs.html
- Rat reproducibility: https://dcmri.org/examples/liver/plot_tristan_repro.html
- Healthy volunteers: https://dcmri.org/examples/liver/plot_tristan_volunteers_2scan.html
- Patients: https://dcmri.org/examples/liver/plot_tristan_patients.html
Version history
- v0.0.6
- Rat data separated out per study in line with the human data
- v0.0.5
- Removed non-kinetic data due to a miblab database restructure.
- v0.0.4
- Added covariates for LDS subjects
- v0.0.3
- Added results for all human data
- v0.0.2
- Removed duplicate human results and combined all controls without treatment in a single file
- Unique naming of subject ID's by adding a study acronym to the subject number: LDS for Leeds subjects, SHF for Sheffield subjects and GOT for Gothenburg subjects
- v0.0.1
- Combined various formats of previous studies in a coherent dmr format
Datasets
tristan_humans_healthy_rifampicin
The data were acquired in the aorta and liver of 8 healthy volunteers with dynamic gadoxetate-enhanced MRI, before and after administration of a drug (rifampicin) which is known to inhibit liver function. The assessments were done on two separate visits at least 2 weeks apart. On each visit, the volunteer had two scans each with a separate contrast agent injection of a quarter dose each. the scans were separated by a gap of about 1 hour to enable gadoxetate to clear from the liver. This design was deemed necessary for reliable measurement of excretion rate when liver function was inhibited.
The research question was to what extent rifampicin inhibits gadoxetate uptake rate from the extracellular space into the liver hepatocytes (khe, mL/min/100mL) and excretion rate from hepatocytes to bile (kbh, mL/100mL/min). 2 of the volunteers only had the baseline assessment, the other 8 volunteers completed the full study. The results showed consistent and strong inhibition of khe (95%) and kbh (40%) by rifampicin. This implies that rifampicin poses a risk of drug-drug interactions (DDI), meaning it can cause another drug to circulate in the body for far longer than expected, potentially causing harm or raising a need for dose adjustment.
The following data are available for each subject (see data.csv for more detail):
- time_1: acquisition times of the first scan
- time_2: acquisition times of the second scan
- aorta_1: aorta signals in the first scan
- aorta_2: aorta signals in the second scan
- liver_1: liver signals in the first scan
- liver_2: liver signals in the second scan
- aorta_1_accept: valid aorta signals in the first scan
- aorta_2_accept: valid aorta signals in the second scan
- liver_1_accept: valid liver signals in the first scan
- liver_2_accept: valid liver signals in the second scan
- weight: subject weight in kg.
- dose_1: contrast agent doses of first scan in mL/kg.
- dose_2: contrast agent doses of second scan in mL/kg.
- rate: contrast agent injection rate in mL/sec.
- FA_1: Flip angle in degrees of the first scan
- FA_2: Flip angle in degrees of the second scan
- TR: repetition time in sec
- t0: baseline length
- T1_aorta_1: precontrast T1 of blood
- T1_aorta_2: T1 of blood after 1st dynamic
- T1_aorta_3: T1 of blood at the start of the 2nd scan
- T1_liver_1: precontrast T1 of the liver
- T1_liver_2: T1 of the liver after 1st dynamic
- T1_liver_3: T1 of the liver at the start of the 2nd scan
- liver_volume: liver volume in mL.
Please reference the following abstract when using these data (manuscript in preparation):
Thazin Min, Marta Tibiletti, Paul Hockings, Aleksandra Galetin, Ebony Gunwhy, Gerry Kenna, Nicola Melillo, Geoff JM Parker, Gunnar Schuetz, Daniel Scotcher, John Waterton, Ian Rowe, and Steven Sourbron. Measurement of liver function with dynamic gadoxetate-enhanced MRI: a validation study in healthy volunteers. Proc Intl Soc Mag Reson Med, Singapore 2024.
tristan_humans_healthy_metformin
Data from a similar experiment as the rifampicin study in healthy volunteers, but with the drug metformin and performed in another center with a different scanner vendor. The study includes 6 volunteers.
The variables are the same as in the rifampicin study.
Manuscript in preparation.
tristan_humans_healthy_ciclosporin
Data from a similar experiment as the metformin study in healthy volunteers, but with the drug ciclosporin.
The variables are the same as in the rifampicin study.
Manuscript in preparation.
tristan_humans_healthy_controls
Five subjects enrolled in the rifampicin, metformin and ciclosporin studies had their baseline assessment but did not go on to have the the treatment visit, for various reasons. These data are combined together in this file. They can be added to the baseline data of the other studies to form a control cohort.
tristan_humans_patients_rifampicin
The data were acquired in the aorta and liver in 3 patients with dynamic gadoxetate-enhanced MRI. The study participants take rifampicin as part of their routine clinical workup, with an aim to promote their liver function. For this study, they were taken off rifampicin 3 days before the first scan, and placed back on rifampicin 3 days before the second scan. The aim was to determine the effect if rifampicin in uptake and excretion function of the liver.
The data confirmed that patients had significantly reduced uptake and excretion function in the absence of rifampicin. Rifampicin administration improved their excretory function but had no effect on their uptake function.
The variables are the same as in the rifampicin study in healthy volunteers, but the patient study was performed in a different center.
Manuscript in preparation.
tristan_rats_study_01_chronic_rifampicin_placebo
tristan_rats_study_02_chronic_cyclosporine_placebo
tristan_rats_study_03_single_bosentan
tristan_rats_study_04_placebo_rifampicin
tristan_rats_study_05_single_asunaprevir
tristan_rats_study_06_single_pioglitazone
tristan_rats_study_07_single_ketoconazole
tristan_rats_study_08_single_cyclosporine
tristan_rats_study_09_single_placebo
tristan_rats_study_10_single_bosentan
tristan_rats_study_11_control
tristan_rats_study_12_single_rifampicin
tristan_rats_study_13_field_strength
The following data are available for each subject (see data.csv for more detail):
- time: array of time points in sec
- spleen: array of spleen signals in arbitrary units
- liver: array of liver signals in arbitrary units.
- FA: Flip angle in degrees
- TR: repetition time in sec
- n0: number of precontrast acquisitions
- study: an integer identifying the substudy the scan was taken in
- subject: a study-specific identifier of the subject in the range 1-6.
- visit: either 1 (baseline) or 2 (drug or vehicle/saline).
- center: center wehere the study was performed, either E, G or D.
- field_strength: B0-field of scanner on whuch the study was performed
- substance: what was injected, eg. saline, vehicle or drug name.
- BAT: Bolus arrival time
- duration: duration on the injection in sec.
Ebony R. Gunwhy, Catherine D. G. Hines, Claudia Green, Iina Laitinen, Sirisha Tadimalla, Paul D. Hockings, Gunnar Schütz, J. Gerry Kenna, Steven Sourbron, and John C. Waterton. Assessment of hepatic transporter function in rats using dynamic gadoxetate-enhanced MRI: A reproducibility study. MAGMA. 2024 Aug;37(4):697-708. doi: 10.1007/s10334-024-01192-5.
Melillo N, Scotcher D, Kenna JG, Green C, Hines CDG, Laitinen I, Hockings PD, Ogungbenro K, Gunwhy ER, Sourbron S, et al. Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats. Pharmaceutics. 2023; 15(3):896.
Mikael Montelius, Steven Sourbron, Nicola Melillo, Daniel Scotcher, Aleksandra Galetin, Gunnar Schuetz, Claudia Green, Edvin Johansson, John C. Waterton, and Paul Hockings. Acute and chronic rifampicin effect on gadoxetate uptake in rats using gadoxetate DCE-MRI. Int Soc Mag Reson Med 2021; 2674.
Files
tristan_humans_healthy_ciclosporin.dmr.zip
Files
(3.1 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:91e5ef15f2f44c26b8af16baf5ef3bf6
|
528.7 kB | Preview Download |
|
md5:ec64cbdf86261e9210555582e4d849c3
|
244.2 kB | Preview Download |
|
md5:a3446a00533d6198ea580b7dbfcde5dc
|
481.5 kB | Preview Download |
|
md5:4c349447fc3a00654b35922325b3d5f1
|
1.6 MB | Preview Download |
|
md5:c17b17f60350c7032e89809d956c135c
|
186.5 kB | Preview Download |
|
md5:5365bdb04be4176816480cb88ffe1fc3
|
14.3 kB | Preview Download |
|
md5:6abff458a0231a960cd3094f8f05c285
|
11.3 kB | Preview Download |
|
md5:e03cece26ee711a55caedd8cc485a94e
|
4.3 kB | Preview Download |
|
md5:1638405d31e0fc5b071c76fb5c6b1e3e
|
5.4 kB | Preview Download |
|
md5:496cd37be63685ebacccd15bca1e06f0
|
3.7 kB | Preview Download |
|
md5:8177c360520a444884d0328a13096e75
|
3.7 kB | Preview Download |
|
md5:364987cb0cd386fd34884082a6d3f145
|
2.7 kB | Preview Download |
|
md5:dc1668c8dc89338ec618fc53341c657c
|
2.9 kB | Preview Download |
|
md5:864d12629d49b6e4d0d7c1f62f6eeb27
|
2.1 kB | Preview Download |
|
md5:e041adbd2858de1e5582b8e8c8b20fba
|
4.3 kB | Preview Download |
|
md5:47b04f611c428cb3437aa81198d3756f
|
2.6 kB | Preview Download |
|
md5:56aff691bbb457880dc090d050d679ed
|
2.3 kB | Preview Download |
|
md5:b3723c262fd0ac2e7a8fdd6311660a24
|
3.7 kB | Preview Download |
Additional details
Funding
Software
- Development Status
- Active